dalteparin has been researched along with Vascular Diseases in 9 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have previously reported an improved outcome of chronic diabetic foot ulcers during treatment with dalteparin." | 9.12 | Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. ( Apelqvist, J; Blombäck, M; Eliasson, B; Eriksson, JW; Fagrell, B; Hamsten, A; Jörneskog, G; Kalani, M; Silveira, A; Torffvit, O, 2007) |
| " We have previously reported an improved outcome of chronic diabetic foot ulcers during treatment with dalteparin." | 5.12 | Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. ( Apelqvist, J; Blombäck, M; Eliasson, B; Eriksson, JW; Fagrell, B; Hamsten, A; Jörneskog, G; Kalani, M; Silveira, A; Torffvit, O, 2007) |
| "This study was designed to assess whether use of enoxaparin during percutaneous coronary intervention (PCI) increased bleeding compared with unfractionated heparin, in addition to background therapy with eptifibatide." | 5.10 | Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. ( Bhatt, DL; Breall, JA; Casterella, PJ; Cohen, M; Corrigan, VE; Eaton, GM; Lee, BI; Lincoff, AM; Moses, JW; Pulsipher, M; Rogers, M; Ryan, TJ; Sklar, MA, 2003) |
| "Pain is the most prominent symptom of vasoocclusion, and hypercoagulability is a well-established pathogenic phenomenon in people with sickle cell disease." | 2.50 | Low-molecular-weight heparins for managing vasoocclusive crises in people with sickle cell disease: a summary of a cochrane systematic review. ( Fedorowicz, Z; van Zuuren, EJ, 2014) |
| " Moreover, subcutaneous parnaparin has a greater bioavailability and longer half-life than heparin, permitting once-daily administration for the prophylaxis of deep venous thrombosis (DVT) or the treatment of established vascular disorders." | 2.39 | Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders. ( Faulds, D; Frampton, JE, 1994) |
| "Background: Severe progression of coronavirus disease 2019 (COVID-19) causes respiratory failure and critical illness." | 1.72 | HIGH HEPARANASE LEVEL IN SURVIVORS OF COVID-19 - INDICATOR OF VASCULAR AND PULMONARY RECOVERY? ( Adam, EH; Brkic, D; Heinicke, U; Neb, H; Ruskowski, K; Sonntagbauer, M; Talbot, SR; von Knethen, A; Zacharowski, K, 2022) |
| " Subtherapeutic doses of tinzaparin combined with abciximab or roxifiban resulted in a distinct synergy that improved anticoagulant and antiplatelet efficacy mediated by TF, fXa, or thrombin." | 1.31 | Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders. ( Mousa, SA, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Frampton, JE | 1 |
| Faulds, D | 1 |
| Neb, H | 1 |
| Talbot, SR | 1 |
| Ruskowski, K | 1 |
| Brkic, D | 1 |
| Sonntagbauer, M | 1 |
| Adam, EH | 1 |
| von Knethen, A | 1 |
| Zacharowski, K | 1 |
| Heinicke, U | 1 |
| Ghaffarian, K | 1 |
| Furin, M | 1 |
| Bassett, R | 1 |
| Bhatt, DL | 1 |
| Lee, BI | 1 |
| Casterella, PJ | 1 |
| Pulsipher, M | 1 |
| Rogers, M | 1 |
| Cohen, M | 1 |
| Corrigan, VE | 1 |
| Ryan, TJ | 1 |
| Breall, JA | 1 |
| Moses, JW | 1 |
| Eaton, GM | 1 |
| Sklar, MA | 1 |
| Lincoff, AM | 1 |
| Brieger, D | 1 |
| Solanki, V | 1 |
| Gaynor, M | 1 |
| Booth, V | 1 |
| MacDonald, R | 1 |
| Freedman, SB | 1 |
| Kalani, M | 1 |
| Silveira, A | 1 |
| Blombäck, M | 1 |
| Apelqvist, J | 1 |
| Eliasson, B | 1 |
| Eriksson, JW | 1 |
| Fagrell, B | 1 |
| Torffvit, O | 1 |
| Hamsten, A | 1 |
| Jörneskog, G | 1 |
| van Zuuren, EJ | 1 |
| Fedorowicz, Z | 1 |
| Qari, MH | 1 |
| Aljaouni, SK | 1 |
| Alardawi, MS | 1 |
| Fatani, H | 1 |
| Alsayes, FM | 1 |
| Zografos, P | 1 |
| Alsaigh, M | 1 |
| Alalfi, A | 1 |
| Alamin, M | 1 |
| Gadi, A | 1 |
| Mousa, SA | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Double-blind, Placebo Controlled, Multi-national Study of Therapeutic Anticoagulation Strategy for Acute Chest Syndrome in Adults[NCT02580773] | Phase 3 | 200 participants (Anticipated) | Interventional | 2016-12-16 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for dalteparin and Vascular Diseases
| Article | Year |
|---|---|
Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.
Topics: Absorption; Animals; Biological Availability; Blood Coagulation; Half-Life; Heparin; Heparin, Low-Mo | 1994 |
Low-molecular-weight heparins for managing vasoocclusive crises in people with sickle cell disease: a summary of a cochrane systematic review.
Topics: Anemia, Sickle Cell; Female; Fibrinolytic Agents; Hemolysis; Heparin, Low-Molecular-Weight; Humans; | 2014 |
3 trials available for dalteparin and Vascular Diseases
| Article | Year |
|---|---|
Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study.
Topics: Adult; Angioplasty, Balloon, Coronary; Anticoagulants; Coronary Angiography; Drug Therapy, Combinati | 2003 |
Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers.
Topics: Aged; Dalteparin; Diabetes Mellitus; Double-Blind Method; Female; Fibrinolytic Agents; Foot Ulcer; H | 2007 |
Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Double-Blind Method; Female; Fibrinolyt | 2007 |
4 other studies available for dalteparin and Vascular Diseases
| Article | Year |
|---|---|
HIGH HEPARANASE LEVEL IN SURVIVORS OF COVID-19 - INDICATOR OF VASCULAR AND PULMONARY RECOVERY?
Topics: Cohort Studies; COVID-19; COVID-19 Drug Treatment; Endothelium, Vascular; Enoxaparin; Glucuronidase; | 2022 |
STEMI in a young female? Consider spontaneous peripartum coronary artery dissection.
Topics: Adult; Anticoagulants; Coronary Angiography; Coronary Vessel Anomalies; Diagnosis, Differential; Eno | 2017 |
Optimal strategy for administering enoxaparin to patients undergoing coronary angiography without angioplasty for acute coronary syndromes.
Topics: Acute Disease; Aged; Anticoagulants; Cardiac Catheterization; Coronary Angiography; Coronary Disease | 2002 |
Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
Topics: Amidines; Antifibrinolytic Agents; Blood Coagulation; Clot Retraction; Dose-Response Relationship, D | 2000 |